November 24, 2016 - By Ellis Scott · 0 Comments
The stock of Amphastar Pharmaceuticals Incorporated (NASDAQ:AMPH) registered a decrease of 5.4% in short interest. AMPH’s total short interest was 3.30M shares in November as published by FINRA. Its down 5.4% from 3.49M shares, reported previously. With 269,800 shares average volume, it will take short sellers 12 days to cover their AMPH’s short positions. The short interest to Amphastar Pharmaceuticals Incorporated’s float is 9.35%. The stock increased 3.98% or $0.79 on November 23, hitting $20.65. About 268,717 shares traded hands. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 57.51% since April 22, 2016 and is uptrending. It has outperformed by 52.10% the S&P500.
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $938.58 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. It has a 45.75 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.
Insitutional Activity: The institutional sentiment increased to 3.17 in Q2 2016. Its up 1.07, from 2.1 in 2016Q1. The ratio improved, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Blackrock Fund Advisors holds 0.01% or 1.50M shares in its portfolio. The United Kingdom-based Blackrock Grp Incorporated Limited has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Legal And General Group Public Ltd Liability last reported 5,695 shares in the company. Springbok Cap Management Ltd Liability Com holds 21,078 shares or 0.05% of its portfolio. Wells Fargo Mn accumulated 27,864 shares or 0% of the stock. Blackrock Institutional Tru Communication Na accumulated 0% or 824,113 shares. Morgan Stanley has 0% invested in the company for 47,794 shares. Shinko Asset Limited holds 0.03% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 250,331 shares. Essex Invest Mgmt Co Ltd Llc owns 105,239 shares or 0.28% of their US portfolio. Martingale Asset Lp last reported 0.02% of its portfolio in the stock. Moreover, Connor Clark And Lunn Inv Mngmt has 0% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 16,000 shares. Credit Suisse Ag accumulated 66,912 shares or 0% of the stock. Eam Lc accumulated 0.6% or 246,805 shares. Endurant Lp holds 0.26% or 48,825 shares in its portfolio. Goldman Sachs Gp holds 0% or 53,070 shares in its portfolio.
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Amphastar Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has “Buy” rating given on Monday, August 10 by Zacks. On Tuesday, August 18 the stock rating was upgraded by Zacks to “Hold”. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has “Outperform” rating given on Friday, February 19 by Wells Fargo. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has “Buy” rating given on Tuesday, January 19 by Jefferies. The company was initiated on Wednesday, June 29 by BMO Capital Markets. As per Tuesday, August 9, the company rating was maintained by Jefferies. Needham maintained Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Tuesday, May 10 with “Buy” rating.
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment makes, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment makes and distributes recombinant human insulin and porcine insulin. The Firm makes and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Another recent and important Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) news was published by Fool.com which published an article titled: “Why Amphastar Pharmaceuticals, Inc. is Soaring Today” on September 20, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott